Policy & Regulation
FDA's One-Trial Default Lands Just as BCI Companies Approach Pivotal Studies
The agency's new policy ending the two-trial requirement was written for drugs, but brain implant makers watching Synchron, Neuralink, and Paradromics navigate FDA are asking whether the same logic could eventually ease their path.